Dana-Farber Cancer Institute Inc. and Cornell University have disclosed phosphatidylinositol 5-phosphate 4-kinase type-2 γ (PIP4K2C) inhibitors and its PROTAC compounds reported to be useful for the treatment of cancer, infections, immunodeficiency disorders, insulin resistance, autoimmune and Huntington's disease.

The National Center for Global Health and Medicine (NCGM) and Tokyo Medical and Dental University have divulged 3C-like protease (3CLpro) (SARS-CoV-2) inhibitors reported to be useful for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections (COVID-19).

Ligand Pharmaceuticals Inc. has divulged prodrugs of clevudine and telbivudine reported to be useful for the treatment of hepatitis, diabetes, malaria, obesity, atherosclerosis, cancer, viral infections and cancer.

Cytosinlab Therapeutics Co. Ltd. has divulged protein arginine N-methyltransferase 1 (PRMT1) inhibitors reported to be useful for the treatment of cancer, cardiovascular disorder, malaria, AIDS, gout, diabetes, renal failure and cocaine dependency, among others.

Bristol Myers Squibb Co. has identified nonreceptor tyrosine-protein kinase TYK2 inhibitors reported to be useful for the treatment of amyotrophic lateral sclerosis, Alzheimer's and Parkinson's disease, multiple sclerosis, neuromyelitis optica and optic neuritis.

Syndax Pharmaceuticals Inc., Syngene International Ltd. and Vitae Pharmaceuticals Inc. have patented menin (MEN1)/MLL interaction inhibitors reported to be useful for the treatment of cancer.

Shanghai Pharmaceuticals Holding Co. Ltd. has described quinazoline compounds acting as TNF-α and/or IL-6 and/or IL-1β production inhibitors reported to be useful for the treatment of cancer, asthma, malaria, viral infections, autoimmune diseases, cardiovascular disorders, chronic obstructive pulmonary disease (COPD) and transplant rejection.

Wigen Biomedicine Technology (Shanghai) Co. Ltd. has divulged pyrrolopyrimidine derivatives containing a pyrazine structure acting as Wee1-like protein kinase (Wee1) inhibitors reported to be useful for the treatment of cancer.

Opna Bio AG has identified transcriptional coactivator YAP1/transcriptional enhancer factor (TEAD) interaction inhibitors reported to be useful for the treatment of arrhythmogenic right ventricular cardiomyopathy, cancer, Holt-Oram syndrome, neurofibromatosis type 2, polycystic kidney and Alzheimer's disease.